Although the FDA‐approved FASN inhibitor, Orlistat, is shown to be effective in reducing tumor cells in vivo, one main limitation is its extremely low oral bioavailability, as Orlistat exerts its effects primarily in the gastrointestinal tract, where it inactivates pancreatic lipase (McNeely & Benfield, 1998). Here, PNLIP is linked to neoplasm.